Latest Update on Taysha Gene Therapy

Summary

• The REVEAL Adolescent & Adult Study (females age 12+) will expand into the United States (U.S.) following submission of an investigational new drug application to the Food and Drug Administration (FDA).
• The REVEAL Adolescent & Adult Study will proceed to the next dose cohort (or “group”)
  following approval from the study’s Independent Data Monitoring Committee to move to the
  next dose level. Dosing of the first participant in cohort two (high dose) is expected in Q2 2024.
• The IDMC also approved the dosing of the second participant in cohort one (low dose) of the
  REVEAL Pediatric Study, which is expected to take place in Q1 2024.